Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY presents the results of the Phase I/IIa TranStar101 trial (NCT04396821) evaluating the safety, tolerability, and pharmacokinetics of the monoclonal antibody osemitamab with nivolumab. Osemitamab is a next generation inhibitor of claudin 18.2 (CLDN18.2), an important biomarker expressed in locally advanced or metastatic solid tumors. Dr Janjigan briefly highlights the findings of Phase III studies on zolbetuximab, another anti-CLDN18.2 monoclonal antibody, with promising results for progression free survival. This TranStar101 trial successfully employed a combinatory treatment approach to evaluate the use of chemotherapy, a checkpoint inhibitor targeting PD-1, and osemitamab. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
